Posted by Michael Wonder on 07 Jul 2022
Vertex announces letter of intent with the pan-Canadian Pharmaceutical Alliance for public reimbursement of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children with cystic fibrosis ages 6 and older
7 July 2022 - Vertex Pharmaceuticals today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance, which represents an agreement in principle regarding the public reimbursement of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for patients ages 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
This is an amendment of the previous letter of intent which includes Trikafta for ages 12 years and older, Kalydeco (ivacaftor), and Orkambi (lumacaftor/ivacaftor).
